Edition:
United Kingdom

Neurotrope Inc (NTRP.OQ)

NTRP.OQ on NASDAQ Stock Exchange Capital Market

9.41USD
21 Jun 2018
Change (% chg)

$0.06 (+0.64%)
Prev Close
$9.35
Open
$9.29
Day's High
$9.47
Day's Low
$9.01
Volume
9,443
Avg. Vol
6,153
52-wk High
$11.19
52-wk Low
$3.41

Latest Key Developments (Source: Significant Developments)

Neurotrope Inc - On May 4 Neurotrope Bioscience Executed A Services Agreement With Worldwide Clinical Trials
Thursday, 10 May 2018 

May 10 (Reuters) - Neurotrope Inc ::NEUROTROPE INC - ON MAY 4 NEUROTROPE BIOSCIENCE EXECUTED A SERVICES AGREEMENT WITH WORLDWIDE CLINICAL TRIALS.NEUROTROPE - DEAL RELATES TO SERVICES FOR CONFIRMATORY PHASE 2 STUDY OF BRYOSTATIN IN TREATMENT OF MODERATELY SEVERE TO SEVERE ALZHEIMERS DISEASE.NEUROTROPE INC - NEUROTROPE AND NEUROTROPE BIOSCIENCE EXPECT THAT FIRST STUDY SITE WILL BE INITIATED DURING Q2 OF 2018.NEUROTROPE INC - PER AGREEMENT TOTAL ESTIMATED BUDGET FOR SERVICES, INCLUDING PASS-THROUGH COSTS, IS APPROXIMATELY $6.9 MILLION.  Full Article

Neurotrope Appoints Charles S. Ryan As CEO
Monday, 18 Dec 2017 

Dec 18 (Reuters) - Neurotrope Inc ::NEUROTROPE APPOINTS CHARLES S. RYAN AS CHIEF EXECUTIVE OFFICER.NEUROTROPE INC - ‍ APPOINTMENT OF CHARLES RYAN FOLLOWS RESIGNATION OF SUSANNE WILKE, PHD, AS CHIEF EXECUTIVE OFFICER AND DIRECTOR​.NEUROTROPE INC - RYAN BECOMES A DIRECTOR OF COMPANY EFFECTIVE IMMEDIATELY AND WILL ASSUME HIS RESPONSIBILITIES AS CEO EFFECTIVE FEBRUARY 15, 2018.  Full Article

BRIEF-Neurotrope's Bryostatin Improves Cognition In Patients

* NEUROTROPE'S BRYOSTATIN IMPROVES COGNITION IN PATIENTS WITH ADVANCED ALZHEIMER'S DISEASE BASED ON FURTHER ANALYSIS OF PHASE 2 CLINICAL TRIAL DATA Source text for Eikon: Further company coverage: